AVBP - CIK 0001868279
ArriVent BioPharma, Inc. trades as AVBP and has a market capitalization of $1.41 B, making it the #2376 largest US-listed company by market value. This page tracks ArriVent BioPharma, Inc. through 144 SEC filings, with financial statements and metrics updated as new reports are filed.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-11 |
| Prospectus supplement | 424B5 | 2026-05-11 |
| Quarterly report | 10-Q | 2026-05-11 |
| Major company event | 8-K | 2026-05-11 |
| SCHEDULE 13G/A | - | 2026-05-06 |
| Annual report to shareholders | ARS | 2026-04-28 |
| Proxy materials | DEFA14A | 2026-04-28 |
| Proxy statement | DEF 14A | 2026-04-28 |
ArriVent BioPharma Reports First Quarter 2026 Financial Results | ArriVent Biopharma
ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers | ArriVent Biopharma
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting | ArriVent Biopharma
ArriVent BioPharma Reports Full Year 2025 Financial Results | ArriVent Biopharma
ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer | ArriVent Biopharma
The largest companies sharing ArriVent BioPharma, Inc.'s SEC industry classification (pharmaceutical preparations).
ArriVent BioPharma, Inc. (AVBP) has a market capitalization of $1.41 B as of 2026-06-10, ranking #2376 among US-listed companies.
In its latest fiscal year ArriVent BioPharma, Inc. reported a net loss of $166.31M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.